Gleevec Increases Levels of the Amyloid Precursor Protein Intracellular Domain and of the Amyloid-β–degrading Enzyme Neprilysin
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Amyloid-β (Aβ) deposition is a major pathological hallmark of Alzheimer's disease. Gleevec, a known tyrosine kinase inhibitor, has been shown to lower Aβ secretion, and it is considered a potential basis for novel therapies for Alzheimer's disease. Here, we show that Gleevec decreases Aβ levels without the inhibition of Notch cleavage by a mechanism distinct from γ-secretase inhibition. Gleevec does not influence γ-secretase activity in vitro; however, treatment of cell lines leads to a dose-dependent increase in the amyloid precursor protein intracellular domain (AICD), whereas secreted Aβ is decreased. This effect is observed even in presence of a potent γ-secretase inhibitor, suggesting that Gleevec does not activate AICD generation but instead may slow down AICD turnover. Concomitant with the increase in AICD, Gleevec leads to elevated mRNA and protein levels of the Aβ-degrading enzyme neprilysin, a potential target gene of AICD-regulated transcription. Thus, the Gleevec mediated-increase in neprilysin expression may involve enhanced AICD signaling. The finding that Gleevec elevates neprilysin levels suggests that its Aβ-lowering effect may be caused by increased Aβ-degradation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943 · cited 2×
“H4-Fe65i cells express human Fe65-Myc under the control of the tet off system (Gossen and Bujard, 1992).”
BackgroundMethodCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757 · cited 2×
“Less reduction in A in H4-APPswe cells could be explained by the fact that these cells secrete six to eightfold higher levels of A than H4-APPwt cells (Figure 6B), due to the Swedish mutation ( Citron et al., 1992; Cai et al., 1993).”
BackgroundRelease of Excess Amyloid β Protein from a Mutant Amyloid β Protein Precursor
Cai, X.-D., Golde, T. E., & Younkin, S. G. (1993) · Science · doi:10.1126/science.8424174 · Cited by 913 · cited 1×
“Less reduction in A in H4-APPswe cells could be explained by the fact that these cells secrete six to eightfold higher levels of A than H4-APPwt cells (Figure 6B), due to the Swedish mutation (Citron et al., 1992; Cai et al., 1993).”
BackgroundAplin, A. E., Gibb, G. M., Jacobsen, J. S., Gallo, J., & Anderton, B. H. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67020699.x · Cited by 201 · cited 1×
“Among the several kinases that have been described to phosphorylate APP at T668 (Suzuki et al., 1994; Aplin et al., 1996; Iijima et al., 2000; Taru and Suzuki, 2004; Kimberly et al., 2005), the c-Jun NH2terminal kinase (JNK) seems to play an important role in vivo (Kimberly et al.”
Background
Cited by
The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol
Barrett, P. J., Song, Y., Van Horn, W. D., Hustedt, E. J., Schafer, J. M., Hadziselimovic, A., Beel, A. J., & Sanders, C. R. (2012) · Science · doi:10.1126/science.1219988 · Cited by 467
The amyloid precursor protein: A biochemical enigma in brain development, function and disease
Nalivaeva, N. N., & Turner, A. J. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.05.010 · Cited by 273
Aβ-degrading enzymes: potential for treatment of Alzheimer disease
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182345e46 · Cited by 265
“The tyrosine kinase inhibitor, imatinib mesilate (Gleevec), increases APP intracellular domain and NEP and lowers cellular AA (235).”
BackgroundMechanisms of Amyloid-β Peptide Clearance: Potential Therapeutic Targets for Alzheimer's Disease
Yoon, S.-S., & AhnJo, S.-M. (2012) · Biomolecules and Therapeutics · doi:10.4062/biomolther.2012.20.3.245 · Cited by 205
Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease?
Nalivaeva, N. N., Beckett, C., Belyaev, N. D., & Turner, A. J. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07510.x · Cited by 169
Metadata
- Authors
- Eisele, Y. S., Baumann, M., Klebl, B., Nordhammer, C., Jucker, M., & Kilger, E.
- Venue
- Molecular Biology of the Cell
- Published
- 2007-09
- Volume
- 18
- Issue
- 9
- Pages
- 3591-3600
- ISSN
- 1059-1524 (ISSN-L)
- 1939-4586
- OpenAlex
- W2118482957
- Cited by
- 54
- References
- 4
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.